Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

This study investigated the efficacy, safety, and clinical benefit of alemtuzumab (Campath-1H) for patients with relapsed or refractory B-cell chronic lymphocytic leukemia exposed to alkylating agents and having failed fludarabine therapy. Ninety-three patients received alemtuzumab in 21 centers wor... View More